Thane Wettig
Directeur Général chez FIBROGEN, INC.
Fortune : 458 547 $ au 30/04/2024
Postes actifs de Thane Wettig
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| FIBROGEN, INC. | Directeur/Membre du Conseil | 02/10/2023 | - |
| Directeur Général | 23/07/2023 | - | |
| Corporate Officer/Principal | 22/06/2020 | 23/07/2023 |
Historique de carrière de Thane Wettig
Anciens postes connus de Thane Wettig
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Lilly Diabetes | Corporate Officer/Principal | 01/01/1990 | 01/01/2009 |
| Sales & Marketing | 01/01/2009 | - | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2018 | - |
Formation de Thane Wettig
| Washington University in St. Louis | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Lilly Diabetes |
- Bourse
- Insiders
- Thane Wettig
- Expérience